黄迎, 刘亚蕾, 马润然, 李春雨, 马致洁, 景婧, 高源, 沈鹏, 林鸿波, 郭玉明, 柏兆方, 肖小河, 王伽伯. 仙灵骨葆相关肝损伤的临床病例分析及拆方实验研究J. 药学学报, 2021,56(1): 266-273. doi: 10.16438/j.0513-4870.2020-1477
引用本文: 黄迎, 刘亚蕾, 马润然, 李春雨, 马致洁, 景婧, 高源, 沈鹏, 林鸿波, 郭玉明, 柏兆方, 肖小河, 王伽伯. 仙灵骨葆相关肝损伤的临床病例分析及拆方实验研究J. 药学学报, 2021,56(1): 266-273. doi: 10.16438/j.0513-4870.2020-1477
HUANG Ying, LIU Ya-lei, MA Run-ran, LI Chun-yu, MA Zhi-jie, JING Jing, GAO Yuan, SHEN Peng, LIN Hong-bo, GUO Yu-ming, BAI Zhao-fang, XIAO Xiao-he, WANG Jia-bo. Clinical case analysis and disassembled prescription study of liver injury related to Xianling GubaoJ. Acta Pharmaceutica Sinica, 2021,56(1): 266-273. doi: 10.16438/j.0513-4870.2020-1477
Citation: HUANG Ying, LIU Ya-lei, MA Run-ran, LI Chun-yu, MA Zhi-jie, JING Jing, GAO Yuan, SHEN Peng, LIN Hong-bo, GUO Yu-ming, BAI Zhao-fang, XIAO Xiao-he, WANG Jia-bo. Clinical case analysis and disassembled prescription study of liver injury related to Xianling GubaoJ. Acta Pharmaceutica Sinica, 2021,56(1): 266-273. doi: 10.16438/j.0513-4870.2020-1477

仙灵骨葆相关肝损伤的临床病例分析及拆方实验研究

Clinical case analysis and disassembled prescription study of liver injury related to Xianling Gubao

  • 摘要: 仙灵骨葆为骨科常用药,临床疗效好,但近年来发现有致肝损伤风险。本研究通过对文献不良反应报告和重点医院病例进行分析,发现文献检索到的仙灵骨葆肝损伤病例存在较大比例的报告信息不完整,难以准确判断其因果关系。重点医院药物性肝损伤(DILI)病例中,筛选出仙灵骨葆相关肝损伤患者6例,其中2例经整合证据链法评价达到了“临床诊断”标准。进一步对区域全人群健康大数据进行分析,估算其粗发生率为0.034%,属于罕见水平,具有显著的个体差异和特异质属性,仙灵骨葆相关肝损伤总体发生水平低于其他骨病用药。基于免疫应激介导的特异质肝损伤模型,通过拆方研究发现,方中淫羊藿和补骨脂是引起肝损伤的相关药味,全方的肝损伤严重程度弱于淫羊藿和补骨脂,提示方中另外4味药(续断、知母、地黄、丹参)有减轻二者引起的肝损伤作用。进一步进行拆方研究,发现4味药均有减轻淫羊藿和补骨脂所致肝损伤作用,其中丹参的配伍减毒效果最好。综上,仙灵骨葆可能在极少数易感个体引起特异质肝损伤,但发生风险低于其他常用骨病药物。临床应用仙灵骨葆要注意避免在免疫应激患者应用。仙灵骨葆引起肝损伤的主要药味为补骨脂、淫羊藿,且丹参在全方中起到配伍减毒作用。本研究可为仙灵骨葆临床合理用药提供参考。

     

    Abstract: Xianling Gubao is a common and effective medicine in the treatment of orthopedic diseases. In recent years, it has been reported to be associated with liver injury. However, through the analysis of the adverse drug reaction reports and key hospital cases, we found that there is considerable incomplete information in the reports of Xianling Gubao-related liver injury cases retrieved from the literature. Thus, it is difficult to accurately judge causality between the drug and liver injury. Six cases of liver injury related to Xianling Gubao were identified in key hospitals, two of which achieved the clinical diagnosis according to the assessment of the integrated evidence chain method. We further analyzed the public health data of all residents in Yinzhou. The gross incidence rate of Xianling Gubao-related liver injury was 0.034%, which corresponds to a level of rare incidence. This revealed that Xianling Gubao-related liver injury has significant divergence in individuals and an idiosyncratic nature. The gross incidence of liver injury related to Xianling Gubao was lower than that of other medicines for the treatment of orthopedic diseases. Based on the idiosyncratic drug-induced liver injury model mediated by immune stress, it was found that Epimedii Folium and Psoraleae Fructus were the major components that lead to liver injury, and the liver injury caused by a full prescription was less serious than that encountered with only Epimedii Folium and Psoraleae Fructus. This suggests that the other 4 herbs (Dipsaci Radix, Anemarrhenae Rhizoma, Rehmanniae Radix,Salviae Miltiorrhizae Radix et Rhizoma) can prevent/alleviate the liver injury. Through disassembled prescription analysis, we found that the attenuation efficacy of Salviae Miltiorrhizae Radix et Rhizoma was the most significant. In conclusion, Xianling Gubao may cause idiosyncratic liver injury in a tiny minority of susceptible individuals, but the incidence risk is lower than that of other commonly used drugs for orthopedic disease. Xianling Gubao should be discreetly applied to patients with immune stress. The major components that induced liver injury in Xianling Gubao were Epimedii Folium and Psoraleae Fructus, and Salviae Miltiorrhizae Radix et Rhizoma appears to attenuate this toxicity. This study provides a reference for the rational clinical medication with Xianling Gubao.

     

/

返回文章
返回